Keros Therapeutics (KROS) Leases (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Leases data on file, last reported at $16.8 million in Q4 2025.

• For the quarter ending Q4 2025, Leases fell 12.52% year-over-year to $16.8 million; the trailing twelve-month figure through Dec 2025 stood at $16.8 million (down 12.52% YoY), and the FY2025 full-year result was $16.8 million, down 12.52% from the prior year.
• Leases for Q4 2025 stood at $16.8 million, down from $17.5 million in the prior quarter.
• Across five years, Leases topped out at $19.8 million in Q3 2024 and bottomed at $447000.0 in Q3 2022.
• The 5-year median for Leases is $15.2 million (2023), against an average of $10.5 million.
• The widest annual swing landed in 2022, when Leases tumbled 36.14%; it then jumped 3405.37% in 2023.
• A 5-year view of Leases shows it stood at $1.1 million in 2021, then soared by 1343.3% to $15.4 million in 2022, then decreased by 0.43% to $15.3 million in 2023, then advanced by 25.54% to $19.3 million in 2024, then decreased by 12.52% to $16.8 million in 2025.
• The last three Leases figures came in at $16.8 million (Q4 2025), $17.5 million (Q3 2025), and $18.1 million (Q2 2025), per Business Quant data.

Peer Comparison